U.S. Residential REITs Stock News

Earlier this week, China confirmed an order for 200 Boeing aircraft following talks between Presidents Trump and Xi, reviving Boeing’s access to a key aviation market and pairing the deal with a framework for reciprocal tariff reductions on about US$30.00 billion of goods on each side. Although the order fell short of earlier expectations for a larger deal, it still marks Boeing’s first major Chinese commitment in nearly a decade and may help ease trade frictions that had constrained its...

Analog Devices (NasdaqGS:ADI) has agreed to acquire Empower Semiconductor in an all cash deal valued at $1.5b. The transaction is aimed at strengthening Analog Devices' AI focused power management offerings for data centers and compute systems. The deal is expected to close in the second half of 2026, subject to closing conditions and approvals. For investors watching Analog Devices at a current share price of $384.21, this deal follows a period of strong longer term share performance,...

Robinhood Markets (NasdaqGS:HOOD) has relisted Algorand (ALGO) for US users after a multi year freeze tied to regulatory concerns. The company is now included as the reference stock in the newly launched GraniteShares Autocallable HOOD ETF, an income focused product linked to Robinhood's share performance. Both moves highlight fresh developments in Robinhood's crypto offering and its role in structured ETF products. Robinhood's shares recently closed at $75.92, with the stock up 17.2% over...

CoreWeave stock reaction and recent performance snapshot CoreWeave (CRWV) has been on investors’ radar after recent trading that left the stock at US$107.58, with the move pairing solid year to date gains with mixed shorter term returns. Over the past month the stock is down 6.6%, while over the past 3 months it is up 20.5% and over the past year it has gained 7.4%, highlighting uneven shorter term momentum. See our latest analysis for CoreWeave. Stepping back, CoreWeave’s share price return...

Wondering whether ON Semiconductor at around US$109.61 is still offering value, or if most of the opportunity is already reflected in the price. The stock has been volatile lately, with the price falling 7.4% over the past week but still up 26.1% over the past month, 93.3% year to date and 159.2% over the last year. Recent headlines around ON Semiconductor have focused on its role within the broader semiconductor sector and how investor sentiment has shifted as chip related themes stay in...

Selective Insurance Group (SIGI) is back in focus after recent analyst commentary pointed to slowing demand, with estimated sales growth for the next 12 months projected at just 1.7%. See our latest analysis for Selective Insurance Group. Despite concerns about slowing sales, recent trading has been firm, with a 12.13% 1 month share price return and the stock at US$90.69, while the 3 year total shareholder return has declined 3.18%, which hints that longer term momentum has been softer. If...

If you are wondering whether Amphenol stock still offers value after a strong run, or if you may be arriving late to the story, this article explains what the current price could be implying about future expectations. The stock closed at US$124.86, with the share price down 3.4% over the past week and down 17.8% over the past month, while the 1 year return is 47.5% and the 3 year return is described as a very large gain. Recent coverage has focused on Amphenol's role as a major supplier of...

Chevron stock at a glance Chevron (CVX) is drawing attention after its shares recently closed at US$191.01, with investors weighing the integrated energy company’s current value against its recent share performance and latest reported financial figures. See our latest analysis for Chevron. The recent 1-day share price decline of 0.17% sits against a stronger backdrop, with the stock showing a 22.52% year to date share price return and a 47.10% total shareholder return over the past year,...

If you have been watching Waste Management and wondering whether the current price gives you fair value for the risk you take, this article is designed to help you frame that question clearly. The stock last closed at US$217.75, with returns that slipped 0.5% over the past week, 2.5% over the past month, 0.3% year to date, but gained 40.8% over three years and 67.5% over five years. These mixed returns sit against a backdrop where Waste Management continues to be a core player in essential...

If you are wondering whether Spotify Technology's current share price reflects its true worth, you are not alone. This article is designed to help you frame that question clearly. Over the past week the stock has risen 13.3%, while it is down 6.2% over the past month and down 14.8% year to date, with a decline of 23.1% over the last year and long term gains of 231.8% over three years and 103.9% over five years. Recent coverage has focused on Spotify's position as a leading global audio...

Johnson & Johnson (NYSE:JNJ) has launched the Shockwave C2 Aero Coronary IVL Catheter to support treatment of calcified coronary artery disease. The company has also secured naming rights at the New Jersey Innovation Hub, tying its brand to a major center for healthcare research and early stage life sciences companies. These developments expand Johnson & Johnson's MedTech footprint and reinforce its role in supporting healthcare startups. For investors watching NYSE:JNJ, these updates sit...

In recent weeks, Intel’s AI-focused chip push has intersected with multiple developments, including SCRT Labs integrating Intel Trust Authority into SecretVM for default hardware attestation and Intel–linked roles in the Terafab project and a preliminary Apple chip-making arrangement, while shareholder proposals on China risk, human rights due diligence, and chair–CEO separation failed at the May annual meeting. Together with foundry yield improvements, Tenstorrent acquisition talks and...

In the past week, Intuitive Surgical reported strong first-quarter 2026 results, with revenue and earnings per share beating expectations, lifted by higher da Vinci procedure volumes, more system placements, and an upgraded full-year procedure growth outlook alongside anticipated margin expansion despite tariff pressures. The company also unveiled over 100 software and hardware enhancements for its da Vinci 5 ecosystem, signaling a deeper push into digital, connectivity, and force-feedback...

Stock performance context for Stride Stride (LRN) has attracted attention after a mixed run in the stock. The share price is around $87.65, with the stock down about 11% over the past month but higher over the past 3 months. See our latest analysis for Stride. Short term momentum has cooled, with the share price return down 10.66% over the past 30 days, but the year to date share price return of 35.66% and 3 year total shareholder return of 117.60% show a much stronger longer term picture. If...

NextNRG, Inc. has already reported first-quarter 2026 results for the period ended March 31, 2026, posting sales of US$21.06 million versus US$16.27 million a year earlier and a net loss of US$10.73 million compared with US$8.79 million. While the company remained loss-making, the combination of higher revenue and a sharp improvement in basic loss per share from continuing operations to US$0.07 from US$1.59 highlights how operating metrics are shifting as investors reassess the...

Recent performance context for AerCap Holdings (AER) AerCap Holdings (AER) has seen mixed share performance recently, with the stock roughly flat over the past month and down over the past 3 months, despite a positive total return over the past year and over multi year periods. See our latest analysis for AerCap Holdings. Despite some recent pressure, with the 3 month share price return down 7.8% and the year to date share price return down 3.5%, AerCap’s longer term picture looks stronger...

TG Therapeutics (NasdaqCM:TGTX) raised its revenue guidance for 2026. The company cited strong performance of its multiple sclerosis drug Briumvi. It is also advancing clinical studies to test Briumvi in additional autoimmune indications. TG Therapeutics focuses on treatments for autoimmune diseases, with Briumvi at the center of its current commercial efforts in multiple sclerosis. The updated 2026 revenue guidance highlights how Briumvi is shaping the company’s profile, as uptake trends...

McDonald's (MCD) is leaning on new value offerings and premium menu additions to keep cost conscious customers engaged, even as inflation and higher labor and beef costs keep investor attention firmly on the stock. See our latest analysis for McDonald's. Those value deals and premium launches come as the stock works to regain momentum, with a 1-day share price return of 1.40% and a 7-day share price return of 3.35% contrasting with a 90-day share price decline of 13.68% and a 1-year total...

Aktis Oncology stock: key recent moves Aktis Oncology (AKTS) has drawn attention after recent trading left the stock at a last close of $19.12, with short term returns mixed and year to date performance currently showing a double digit decline. See our latest analysis for Aktis Oncology. Recent trading shows momentum fading, with a 7 day share price return of 1.95% lower and a 30 day share price return of 6.73% lower, while the year to date share price return is 14.64% lower from the current...

Devon Energy (NYSE:DVN) has completed a $2.6b acquisition of 16,300 net undeveloped acres in the Delaware Basin. The newly acquired acreage is contiguous with Devon's existing position, supporting longer term development plans. The deal adds to Devon's core asset base and is intended to support its current capital return framework. For investors watching NYSE:DVN, this deal comes as the stock trades around $47.11, with a return of 24.4% year to date and 55.2% over the past year. Those...

Iovance Biotherapeutics recently announced that Interim CEO Fred Vogt and CFO Corleen Roche took part in a fireside chat at the 2026 Jefferies Global Healthcare Conference, while highlighting encouraging real-world data for its FDA-approved TIL therapy Amtagvi in advanced melanoma. The combination of early commercial experience with Amtagvi and efforts to improve manufacturing efficiencies and pursue label expansions underscores how Iovance is trying to scale a complex cell therapy platform...

Monster Beverage buyback announcement Monster Beverage (MNST) has launched a new share repurchase program after its Board of Directors authorized a plan on May 14, 2026, allowing up to US$500 million of common stock to be bought back. See our latest analysis for Monster Beverage. The buyback news lands after a strong run in the stock, with a 30 day share price return of 14.68% and a 1 year total shareholder return of 37.30%, building on 5 year total shareholder returns of 85.02%. If this kind...

Mueller Industries (MLI) has drawn attention after market commentary flagged its stock as trading well above certain intrinsic value estimates, prompting caution just as the company affirmed a quarterly dividend of $0.35 per share. See our latest analysis for Mueller Industries. Recent price action reflects that tension between strong fundamentals and valuation concern, with the share price slipping 4.1% over the past week but still showing a 14.4% year to date share price return and a very...

If you are wondering whether Baidu's current share price really reflects what you are getting for your money, this article breaks down what the numbers say about value so you can judge for yourself. Baidu's stock has been choppy recently, with the share price down about 8.5% over the last week, up 6.2% over the last month, and still down 12.7% year to date, even after a 56.0% gain over the past year and a 10.5% gain over three years. These moves come as Baidu stays in focus for its role in...